AIM ImmunoTech is trading at $0.32, +25.66%, after rising from the August 28 close of $0.26.
- No fresh August 31 company-specific announcement was identified.
- The latest release, dated August 27, announced an on-demand investor conference focused on Ampligen’s pancreatic-cancer program and upcoming trial milestones.
- Broader markets are modestly lower, so macro sentiment does not clearly explain the gain.